Folkehelseinstituttet sin nye årsrapport på legemiddelforbruk i Norge er ute, og den viser igjen en jevn økning. Det ble i 2012 omsatt legemidler til en utsalgspris på ca 20 milliarder kroner, noe som utgjør en kostnadsvekst på 3,5% i forhold til 2011. Legemidler for 18,8 milliarder kroner var til humant bruk, noe som igjen utgjør en økning på 4,3 milliarder i en tiårsperiode.
Salg i milliarder kr av legemidler med markedsføringstillatelse, 2003-2012: (ekskl veterinære legemidler)
2003: 14,5
2004: 15,6
2005: 16,1
2006: 16,5
2007: 17,1
2008: 17,3
2009: 18,2
2010: 17,9
2011: 18,2
2012: 18,8
Les hele rapporten her.
«Medicalization is the process by which human conditions and problems come to be defined and treated as medical conditions, and thus become the subject of medical study, diagnosis, prevention, or treatment. Medicalization can be driven by new evidence or hypotheses about conditions; by changing social attitudes or economic considerations; or by the development of new medications or treatments.
Medicalization is studied from a sociologic perspective in terms of the role and power of professionals, patients, and corporations, and also for its implications for ordinary people whose self-identity and life decisions may depend on the prevailing concepts of health and illness. Once a condition is classified as medical, a medical model of disability tends to be used in place of a social model. Medicalization may also be termed «pathologization» or (pejoratively) «disease mongering«.
Kilden Nyheter 